Volume 145, Issue 4, Pages 740-748.e8 (October 2013) Anti-Rotavirus Protein Reduces Stool Output in Infants With Diarrhea: A Randomized Placebo-Controlled Trial  Shafiqul A. Sarker, Martin Jäkel, Shamima Sultana, Nur H. Alam, Pradip K. Bardhan, Mohammod J. Chisti, Mohammed A. Salam, Winfried Theis, Lennart Hammarström, Leon G.J. Frenken  Gastroenterology  Volume 145, Issue 4, Pages 740-748.e8 (October 2013) DOI: 10.1053/j.gastro.2013.06.053 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Plot of mean daily stool output. Plot of mean daily stool output in g/kg bodyweight for subjects with exclusive rotavirus infection (A) and concomitant infections (B). The illustration is based on the linear mixed effect model A (intention-to-treat population over 4 days) presented in Table 4. Gastroenterology 2013 145, 740-748.e8DOI: (10.1053/j.gastro.2013.06.053) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 Survival curves for the duration of diarrhea according to treatment group (active and placebo) and presence/absence of concomitant infection. Curves are based on intention-to-treat population. The active (ARP1) and placebo groups did not differ in terms of duration of diarrhea. Presence or absence of concomitant infections did not affect duration of diarrhea. Gastroenterology 2013 145, 740-748.e8DOI: (10.1053/j.gastro.2013.06.053) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 1 Trial profile (total cohort). CONSORT (Consolidated Standards of Reporting Trials) Trial Profile. The intention-to-treat population (ITT) was defined as all children that received at least 1 dose of the treatment and were positive for rotavirus infection in stool at admission. The per-protocol (PP) population was composed of all subjects who were eligible for the study and completed the study per the protocol. DF, dark-field. Gastroenterology 2013 145, 740-748.e8DOI: (10.1053/j.gastro.2013.06.053) Copyright © 2013 AGA Institute Terms and Conditions